排序方式: 共有56条查询结果,搜索用时 15 毫秒
1.
Nicole E. Sharp MD FACS Darren B. Sachs DO Nicole M. Melchior DO Philip Albaneze MD FACS Salvatore Nardello DO Elin R. Sigurdson MD PhD FACS Mengying Deng MMath Allison A. Aggon DO FACOS John M. Daly MD FACS Richard J. Bleicher MD FACS 《The breast journal》2021,27(4):335-344
Prospective trials demonstrate that sentinel node (SN) biopsy after neo-adjuvant chemotherapy (NACT) has a significant false-negative rate (FNR) when only 1 or 2 SNs are removed. It is unknown whether this increased FNR correlates with an elevated risk of recurrence. Tumor Registry data at an NCI-Designated Comprehensive Cancer Center were reviewed from 2004 to 2018 for patients having a negative SN biopsy after NACT. Among 190 patients with histologically negative nodes after NACT having 1 (n = 42), 2 (n = 46), and ≥3 (n = 102) SNs, axillary recurrences occurred in 7.14%, 0%, and 1.96% (p = 0.09), breast recurrences occurred in 2.38%, 6.52%, and 0.98% (p = 0.12), and distance recurrences occurred in 16.67%, 8.70%, and 7.84% (p = 0.27), respectively. Time to first recurrence did not differ by SN count (p = 0.41). After adjustment for age, race, clinical stage, and receptor status, there were no differences in the rates of axillary (p = 0.26), breast (p = 0.44), or distance recurrence (p = 0.24) by numbers of SNs harvested. Median follow-up was 46.8 months. Despite higher post-NACT FNRs reported in randomized trials for patients having <3 sentinel nodes, recurrence rates were not significantly different for 1 versus 2 versus ≥3 SNs. This suggests that patients having 1 or 2 post-NACT SNs identified may not necessitate axillary dissection. 相似文献
2.
David P. Goldstein MD Gideon Y. Bachar MD Jane Lea MD Mark G. Shrime MD Rajan S. Patel MB Patrick J. Gullane MB Dale H. Brown MB Ralph W. Gilbert MD John Kim MD Jonathan Waldron MD Bayardo Perez–Ordonez MD Aileen M. Davis PhD Lu Cheng MMath Wei Xu PhD Jonathan C. Irish MD 《Head & neck》2013,35(5):632-641
3.
Impact of p16 expression,nodal status,and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma
下载免费PDF全文
![点击此处可从《Head & neck》网站下载免费的PDF全文](/ch/ext_images/free.gif)
4.
Effectiveness of the STOPP/START (Screening Tool of Older Persons' potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta‐analysis of randomized controlled studies
下载免费PDF全文
![点击此处可从《Journal of clinical pharmacy and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
5.
Background Routine use of axillary lymph node dissection (ALND) has been questioned in elderly women. This study examines whether selective
application of ALND in early stage breast cancer affects breast cancer-related survival.
Methods From the Surveillance, Epidemiology, and End Results (SEER) database, records of women ≥70 years of age with stage I or II
breast cancer diagnosed between 1990 and 1995 were reviewed. Hazard ratios (HR) of cause-specific survival (CSS) between women
receiving ALND and those who did not were compared. To minimize the potential for bias in the selection of women to receive
ALND, HR of CSS was compared within propensity analysis deciles.
Results 20,151 women entered the analysis. Median follow up was 6 years (interquartile range 4.33–7.67 years). Seventy-five percent
underwent ALND. Women with higher risk disease and younger age were more likely to undergo ALND. Five year unadjusted CSS
in women who did and did not receive ALND was 92.1% and 90.6%, respectively, with a HR of 0.85, P = 0.002. Using the propensity analysis method, the adjusted HR for CSS associated with ALND was 0.89, P = 0.066.
Discussion After adjusting for differences in the probability of receiving ALND, no clinically or statistically significant difference
in survival was observed among women who received ALND when compared with those who did not, although we could not account
for differences in co-morbidity or use of systemic therapy between groups.
Conclusion Surgeons select elderly women with early stage breast cancer for ALND with a negligible impact on CSS. 相似文献
6.
7.
Prognostic value of pretreatment circulating neutrophils,monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status
下载免费PDF全文
![点击此处可从《Cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Shao Hui Huang MSc MD MRT John N. Waldron MD Michael Milosevic MD Xiaowei Shen MMath Jolie Ringash MD Jie Su MSc Li Tong BSc Bayardo Perez‐Ordonez MD Ilan Weinreb MD Andrew J. Bayley MD John Kim MD Andrew Hope MD B.C. John Cho MD Meredith Giuliani MD Albiruni Razak MD David Goldstein MD Willa Shi PhD Fei‐Fei Liu MD Wei Xu PhD Brian O'Sullivan MD 《Cancer》2015,121(4):545-555
8.
The role of second‐hand smoke exposure on smoking cessation in non–tobacco‐related cancers
下载免费PDF全文
![点击此处可从《Cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Lawson Eng MD Xin Qiu MMath Jie Su MSc Dan Pringle MScPT Chongya Niu Hon BSc Mary Mahler Rebecca Charow BS Jodie Villeneuve BHSc Oleksandr Halytskyy MD Christine Lam BMedSci Kyoko Tiessen BSc M. Catherine Brown MSc Doris Howell RN PhD Meredith E. Giuliani MBBS MEd Jennifer M. Jones PhD Shabbir M. H. Alibhai MD David P. Goldstein MD Wei Xu PhD Geoffrey Liu MD MSc 《Cancer》2015,121(15):2655-2663
9.
Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial
下载免费PDF全文
![点击此处可从《Cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
10.
Adrian Baranchuk MD Jeff S. Healey MD Kevin E. Thorpe MMath Carlos A. Morillo MD FACC Girish Nair MD Eugene Crystal MD Charles R. Kerr MD FACC Stuart J. Connolly MD FACC CTOPP Investigators 《Heart rhythm》2007,4(8):1024-1028
BACKGROUND: Although several randomized trials have detected no reduction in major cardiovascular events with the routine use of dual-chamber as opposed to ventricular pacemakers, many individuals continue to advocate their use as a means of improving exercise capacity. METHODS: The Canadian Trial of Physiological Pacing (CTOPP) trial is the largest trial comparing ventricular pacing to atrial-based pacing (atrial or dual-chamber) in patients with bradycardia. All patients in this trial were asked to complete a 6-minute hall walk test (6MWT) at the time of their first study follow-up. The distance walked in 6 minutes and the patient's heart rate before and immediately after the walk were recorded. RESULTS: Of the 2568 patients in the CTOPP, 76% completed the 6MWT. The mean distance walked was 350 +/- 127 m in the ventricular pacing group and 356 +/- 127 m in the atrial-based group (P = NS). Similarly, there was no difference in the change in heart rate between the two groups (17 +/- 13 vs. 18 +/- 12 bpm: P = NS). However, among patients with an unpaced heart rate of =60 bpm, patients assigned to atrial-based pacing walked farther than those randomized to ventricular pacing (361 +/- 127 vs. 343 +/- 121 m; P = .04). This was not associated with a difference in heart rate. The use of rate-adaptive pacing, irrespective of the pacing mode, resulted in a greater increase in heart rate with the 6MWT but no increase in the total distance walked. CONCLUSION: The routine use of atrial-based pacemakers, instead of ventricular pacemakers, does not improve exercise capacity, as measured by the 6MWT. However, patients with an unpaced heart rate of =60 bpm may achieve a modest increase in their exercise capacity with atrial-based pacing. 相似文献